Lilly Research Labs et al.; Withdrawal of Approval of 16 New Drug Applications and 30 Abbreviated New Drug Applications

الملخص

The Food and Drug Administration (FDA) is withdrawing approval of 16 new drug applications (NDAs) and 30 abbreviated new drug applications (ANDAs). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.